Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Autor: Hodi, F Stephen, Chesney, Jason, Pavlick, Anna C, Robert, Caroline, Grossmann, Kenneth F, McDermott, David F, Linette, Gerald P, Meyer, Nicolas, Giguere, Jeffrey K, Agarwala, Sanjiv S, Shaheen, Montaser, Ernstoff, Marc S, Minor, David R, Salama, April K, Taylor, Matthew H, Ott, Patrick A, Horak, Christine, Gagnier, Paul, Jiang, Joel, Wolchok, Jedd D, Postow, Michael A
Zdroj: In The Lancet Oncology November 2016 17(11):1558-1568
Databáze: ScienceDirect